文献速递关节外科

全关节置换术中青霉素过敏患者围手术期使用头孢唑林是否安全

Perioperative Cefazolin for Total Joint Arthroplasty Patients Who Have a Penicillin Allergy: Is It Safe?
PubMed 文献 · J Arthroplasty · 2024-04-25

该研究纳入2016至2022年接受初次全髋或全膝关节置换的49842例患者,比较报告青霉素过敏且使用头孢唑林者(4938例)与未使用者的过敏反应和感染率。报告青霉素过敏者使用头孢唑林后过敏反应发生率为0.1%,均为轻微反应。作者认为大多数报告青霉素过敏的患者可安全使用头孢唑林。

要点

  • 报告青霉素过敏患者使用头孢唑林后过敏反应发生率为0.1%(5例),均为轻微皮肤或呼吸症状。
  • 报告青霉素过敏者使用头孢唑林与使用替代抗生素相比,浅表感染、深部感染和艰难梭菌感染率无显著差异。
  • 作者认为大多数报告青霉素过敏的患者可安全使用头孢唑林,与过敏严重程度无关。

核心结论

  • 在5500余例报告青霉素过敏并接受初次全关节置换的患者中,围手术期使用头孢唑林导致0.1%的过敏反应发生率,且临床表现为轻微。
  • 作者认为大多数患者可安全使用头孢唑林,与报告青霉素过敏的严重程度无关。

研究设计与样本

  • 研究纳入2016至2022年接受初次全髋关节置换(25659例)或全膝关节置换(24183例)并接受围手术期静脉抗生素预防的患者,共49842例。
  • 报告青霉素过敏且使用头孢唑林者4938例(89.7%),与报告青霉素过敏但未使用头孢唑林者570例(10.3%)及无青霉素过敏者43359例进行比较。
  • 主要结局为术后72小时内过敏反应发生率,次要结局为90天内浅表感染、深部感染和艰难梭菌感染率。
  • 证据等级为III级。

主要发现

  • 报告青霉素过敏且使用头孢唑林者过敏反应发生率为0.1%(5例),报告青霉素过敏但未使用头孢唑林者为0.2%(1例),P=0.48;无青霉素过敏者为0.02%(11例),P=0.02。
  • 报告青霉素过敏且使用头孢唑林的5例过敏反应均为轻微,表现为皮肤症状(4例)或无呼吸窘迫的呼吸困难(1例),停药并给予抗组胺药和/或皮质类固醇后迅速缓解。
  • 报告青霉素过敏者使用头孢唑林与使用替代围手术期抗生素相比,90天内浅表感染率(0.1% vs 0.2%,P=0.58)、深部感染率(0.3% vs 0.4%,P=0.68)和艰难梭菌感染率(0.04% vs 0%,P=0.99)均无显著差异。

关键数值与推荐

  • 报告青霉素过敏且使用头孢唑林者过敏反应发生率为0.1%(5例),报告青霉素过敏但未使用头孢唑林者为0.2%(1例),P=0.48。
  • 报告青霉素过敏且使用头孢唑林者过敏反应发生率0.1%(5例)与无青霉素过敏者0.02%(11例)比较,P=0.02。
  • 报告青霉素过敏者使用头孢唑林与使用替代抗生素相比,浅表感染率0.1% vs 0.2%(P=0.58),深部感染率0.3% vs 0.4%(P=0.68),艰难梭菌感染率0.04% vs 0%(P=0.99)。

临床怎么用

  • 作者认为,大多数报告青霉素过敏的患者可安全使用头孢唑林,与报告青霉素过敏的严重程度无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cefazolin is the standard of care for perioperative antibiotic prophylaxis in total joint arthroplasty (TJA) in the United States. The potential allergic cross-reactivity between cefazolin and penicillin causes uncertainty regarding optimal antibiotic choice in patients who have a reported penicillin allergy (rPCNA). The purpose of this study was to determine the safety of perioperative cefazolin in PCNA patients undergoing primary TJA. METHODS: We identified all patients (n = 49,842) undergoing primary total hip arthroplasty (n = 25,659) or total knee arthroplasty (n = 24,183) from 2016 to 2022 who received perioperative intravenous antibiotic prophylaxis. Patients who had an rPCNA (n = 5,508) who received cefazolin (n = 4,938, 89.7%) were compared to rPCNA patients who did not (n = 570, 10.3%), and to patients who did not have an rPCNA (n = 43,359). The primary outcome was the rate of allergic reactions within 72 hours postoperatively. Secondary outcomes included the rates of superficial infections, deep infections, and Clostridioides difficile infections within 90 days. RESULTS: The rate of allergic reactions was 0.1% (n = 5) in rPCNA patients who received cefazolin, compared to 0.2% (n = 1) in rPCNA patients who did not (P = .48) and 0.02% (n = 11) in patients who have no rPCNA (P = .02). Allergic reactions were mild in all 5 rPCNA patients who received cefazolin and were characterized by cutaneous symptoms (n = 4) or dyspnea in the absence of respiratory distress (n = 1) that resolved promptly with antibiotic discontinuation and administration of antihistamines and/or corticosteroids. We observed no differences in the rates of superficial infections (0.1 versus 0.2%, P = .58), deep infections (0.3 versus 0.4%, P = .68), or C difficile infections (0.04% versus 0%, P = .99) within 90 days in rPCNA patients who received cefazolin versus alternative perioperative antibiotics. CONCLUSIONS: In this series of more than 5,500 patients who had an rPCNA undergoing primary TJA, perioperative prophylaxis with cefazolin resulted in a 0.1% incidence of allergic reactions that were clinically indolent. Cefazolin can be safely administered to most patients, independent of rPCNA severity. LEVEL OF EVIDENCE: III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Bukowski BR, Torres-Ramirez RJ, Devine D, et al. Perioperative Cefazolin for Total Joint Arthroplasty Patients Who Have a Penicillin Allergy: Is It Safe? J Arthroplasty. 2024. PMID: 38677347. doi:10.1016/j.arth.2024.04.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。